Search for: "In Re: Pfizer Securities Litigation" Results 41 - 60 of 105
Sorted by Relevance | Sort by Date
RSS Subscribe: 20 results | 100 results
22 May 2014, 5:00 am
Pfizer, Inc., 2000 WL 1099884, at *2 & n.1 (S.D.N.Y. [read post]
18 Jan 2007, 6:23 am
Most innovative use of technology in a law dept: John Theriault, vice president, and Mary Ann Sarao, director, global security of Pfizer Inc. [read post]
9 Aug 2012, 5:00 am by Bexis
Pfizer (femoral stem) Deposition1998-09-18 In re AMS Minnesota Penile Prosthesis Litigation Deposition1998-11-25 Mason v. [read post]
12 Nov 2017, 11:00 pm by Kevin LaCroix
Building on its recent decision in In re Petrobras Securities Litigation,[9] the Second Circuit held that a plaintiff need not always offer direct event study evidence of a cause-and-effect relationship between new information and stock price movements before satisfying its burden to prove market efficiency at the class certification stage. [read post]
3 Jan 2013, 2:15 pm by Howard Knopf
There are important issues at stake re what is “substantial” and what is “fair dealing”. [read post]
21 Apr 2011, 1:36 pm by Bexis
We have to admit that we’re scratching out heads about a recent decision out of Alabama that – contrary to everything else we’ve seen – concluded that the manufacturer of a branded drug could be liable in a case where it never sold the generic product that was all the plaintiff every took and thereby (allegedly) suffered injury.It’s not like this issue hasn’t been litigated before in Alabama.The first Alabama case we know of to consider the issue… [read post]
4 Nov 2011, 4:00 am by Steve Nelson
And we’re not just talking about firms that handle so-called “commodity” work. [read post]
25 May 2016, 3:46 pm by Lyle Roberts
” In In re Pfizer Inc. [read post]
11 Apr 2014, 7:41 am
Government is a party to the litigation; and (2) actions in which the rights involved are “integrally related to particular federal government action” or a federal regulatory scheme. 131 S.Ct. at 2611-13. [read post]
8 Jun 2023, 7:43 am by Ashwin Varma
Horizon’s strategy shifted over time, however, with the firm seeking to purchase undervalued therapeutics from bankrupt pharmaceutical companies and then re-launch them. [read post]
30 Sep 2010, 5:58 am by David G. Badertscher
Skeptics have wondered whether litigants might be able to game any substitution. [read post]
14 Apr 2016, 4:59 pm by Kevin LaCroix
  That theory has been a primary enabler of class action securities litigation under Section 10(b) of the Securities Exchange Act of 1934. [read post]